Eli Lilly's TOGETHER-PsA Phase 3b trial showed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) nearly tripled the number of patients achieving at least 50% reduction in psoriatic arthritis (PsA) disease activity after one year compared to Taltz alone. The combination also improved patient-reported outcomes like physical function and fatigue, alongside metabolic measures such as BMI, blood pressure, and cholesterol. These results highlight the benefits of addressing both PsA and obesity-related conditions together, as obesity often worsens PsA outcomes. The findings were presented at ACR Convergence 2026 and published in Arthritis & Rheumatology, supporting a comprehensive treatment approach for patients with PsA and obesity.
Eli Lilly's shares are trading near their 52-week high on Pluang, priced at USD 1,420.09 with a slight 0.85% decline in the last day. As of Nov 11, 2026 21:51 WIB, the stock shows balanced order activity with 51% selling and 49% buying interest.
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
The FDA requires all makers of GLP-1 medications to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and possibly permanent vision loss. This decision follows a review of c...
Eli Lilly's GLP-1 pill Foundayo showed significant improvement in obstructive sleep apnea in Phase 3 trials, with FDA submission planned by end of 2026. Sales jumped from $98 million in Q2 to $184 million in Q3, driving a 28% stock rise this year. Th...
